chronic kidney disease, Ozempic kidney disease approval

Ozempic Now Approved for Kidney Disease Treatment

The FDA has approved Novo Nordisk’s drug Ozempic for a new use: reducing the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). This approval is significant because Ozempic is now the first drug in its class (GLP-1 receptor agonists) with

Semaglutide weight loss

Novo Nordisk’s Higher-Dose Semaglutide Shows Promising Weight Loss Results

Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led

New Study Results Published – Lilly GZGI

Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,

Overweight vs obesity

Overweight vs Obesity – What’s the Difference & Preventing Obesity

Maintaining your ideal weight, eating healthy, and staying physically fit can be a challenge. Especially with today’s busy lifestyle demands. It’s imperative to know if you are overweight or at risk of becoming obese. Both these conditions are linked to many health concerns and can negatively affect your quality of life.   Obesity in adults